Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; Centre de recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM) and Institut du cancer de Montréal, Montréal, Québec, Canada.
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CR-CHUM) and Institut du cancer de Montréal, Montréal, Québec, Canada; Academic Department of Urology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy.
Clin Genitourin Cancer. 2019 Feb;17(1):72-78.e4. doi: 10.1016/j.clgc.2018.09.011. Epub 2018 Sep 22.
The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates is on the rise. However, contemporary data are unavailable. We described community-based NIT rates within 16 Surveillance Epidemiology and End Results (SEER) registries between 2010 and 2014.
We identified 23,360 PCa patients who fulfilled the University of California San Francisco AS criteria (prostate-specific antigen [PSA] < 10 ng/mL, clinical T stage ≤ T2a, Gleason score ≤ 6, and positive cores < 33%). Annual NIT rates as well as patient distribution according to PSA, age, number of positive cores, and clinical T stage were studied. Multivariable logistic regression analysis tested NIT predictors.
Between 2010 and 2014, the NIT rate increased from 30.2% to 57.5% (P = .004). Within 16 SEER registries, NIT rates ranged from 25.9% to 62%. NIT rate increased uniformly within all examined registries. Of patient and tumor characteristics (PSA > 4 ng/mL, cT2a and > 1 positive core) only the proportion of NIT patients aged < 65 years increased over time from 47.3% to 53.2% (P = .03). By multivariable logistic regression analysis predicting NIT rate, older age (odd ratio [OR] = 1.05), more contemporary year of diagnosis (OR = 1.41), and being unmarried (OR = 1.45) and uninsured (OR = 2.41) were independent predictors.
The NIT rate has markedly increased across all examined SEER registries. Nonetheless, important differences distinguish those who received high-end NIT from low-end NIT. PCa characteristics of NIT patients remained unchanged over time. However, in addition to geographical differences in NIT rates, patient characteristics such as age, marital status, and insurance status represent potential NIT access barriers.
在前列腺癌(PCa)主动监测(AS)候选者中,非干预治疗(NIT)的比例正在上升。然而,目前还没有当代的数据。我们描述了 2010 年至 2014 年间在 16 个监测流行病学和最终结果(SEER)登记处进行的基于社区的 NIT 率。
我们确定了 23360 名符合加利福尼亚大学旧金山 AS 标准的 PCa 患者(前列腺特异性抗原[PSA]<10ng/ml、临床 T 分期≤T2a、Gleason 评分≤6、阳性核心<33%)。研究了每年的 NIT 率以及根据 PSA、年龄、阳性核心数量和临床 T 分期的患者分布情况。多变量逻辑回归分析测试了 NIT 的预测因素。
2010 年至 2014 年间,NIT 率从 30.2%上升至 57.5%(P=.004)。在 16 个 SEER 登记处中,NIT 率范围为 25.9%至 62%。在所有检查的登记处中,NIT 率均均匀增加。在患者和肿瘤特征(PSA>4ng/ml、cT2a 和>1 个阳性核心)中,只有年龄<65 岁的 NIT 患者比例从 47.3%增加到 53.2%(P=.03)。通过多变量逻辑回归分析预测 NIT 率,年龄较大(比值比[OR] = 1.05)、诊断较晚(OR = 1.41)、未婚(OR = 1.45)和无保险(OR = 2.41)是独立的预测因素。
所有检查的 SEER 登记处的 NIT 率都有明显增加。然而,重要的区别在于接受高端 NIT 和低端 NIT 的人群。NIT 患者的 PCa 特征随时间变化保持不变。然而,除了 NIT 率的地理差异外,患者特征,如年龄、婚姻状况和保险状况,代表潜在的 NIT 准入障碍。